GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 inhibitor medication had a lower risk of a subsequent stroke, heart attack or death ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke MONDAY, Nov. 11, 2024 ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

Patients with broad range of kidney function show reduced effects following discontinuation after EMPA-KIDNEY trial.

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...